NJAASC has curated authoritative information and a list of resources for our Membership’s reference. We will continue to update this as more information becomes available.
PAST COVID E-BLAST HAVE BEEN ARCHIVED DUE TO SPACE RESTRAINTS AND TO KEEP THINGS CURRENT.
NJAASC SENDS LETTER TO COMMISSIONER ABOUT TESTING AND REPORTING CONCERNS – 7/8/20
In light of the quite serious issues concerning reagent shortages and over burdened labs, NJAASC has sent a
letter to the Commissioner
THIS TEST IS NOT ACCEPTABLE UNDER THE GUIDELINES -7/8/20
Per Dr. Kirn, the BD Veritor test is not acceptable.
Acceptable for use under guidelines?
No - this another antigen test.
AGAIN WITH THE TESTING!- 7/8/20
Just to make it clear since there are still questions.
Currently, there are NO Antigen tests that can be used, that satisfy the Department’s guidelines for ASC pre-op testing.
: I just want to get the answer straight from the expert you!
It is my understanding that right now there are no Antigen tests that can be used for pre-opt ASC testing, per the guidelines.
Tuesday, July 7, 2020 9:31 AM
: Yes correct.
TRANSACTIONS AND VALUATION ISSUES WEBINAR- 7/8/20
Wednesday, July 15, 2020
12:00 p.m. - 1:00 p.m.
Webinar Series: Post COVID-19 Considerations for Healthcare Organizations
As restrictions are gradually lifted, Withum and Brach Eichler invite you to a three-part webinar series offering guidance for your healthcare organization from both the financial and legal perspective. Our experts will address specific concerns you may be facing, including returning to the office, transactions/valuations, and PPP issues, in order to prepare your healthcare organization for a smooth transition back to life in the “new normal.”
Part 2: Post COVID-19 Transactions and Valuation Issues
Since the pandemic began, there’s been a significant disruption in the marketplace in terms of transactions and valuations, particularly for healthcare entities. As we begin to return to work, join our experts as we explore the effect that COVID-19 has had on the industry thus far and considerations for moving forward in light of the ongoing pandemic. As we brace ourselves and our businesses for a second wave, how much will profitability be affected?
John D. Fanburg, Esq
, Managing Member and Chair, Healthcare Law at Brach Eicher, and
, Team Leader of Withum’s Forensic and Valuation Services will dive into the post COVID-19 “new normal.”
Attendees will be able to:
- Assess to what extent NJ M&A activity has slowed or increased as we return to work
- Identify the impact COVID-19 has had on valuations for medical practices that are in due diligence or about to go to market
- Describe how buyout amounts will be calculated post COVID-19 and the effect on retiring physicians
This webinar is anticipated to qualify for 1 NJ CLE/CPE credit.
Lead, Forensic and Valuation Services
Managing Member and Chair, Healthcare Law
Brach Eichler LLC
THIS TEST IS
FOR PRE-OPT TESTING – 7/6/20
See below, as we stated previously in COVID updates, this test Quidel Sofia IS NOT approved for used by ASCs for pre-opt testing. Apparently some centers are using it, and not following the guidelines.
Dr. Kirn- I already know the answer, but I want it to come from you. The test imaged below is not approved for pre-opt testing by ASCs, correct?
Monday, July 6, 2020 12:22 PM